ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
A Supramolecular Material for Controlling Kiwifruit Bacterial Canker.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A GAPlant communications · 2026Article
- Article
- A Supramolecular Material for Controlling Kiwifruit Bacterial Canker.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Kiwifruit, a nutritious fruit consumed globally, is affected by kiwifruit bacterial canker (KBC) caused by Pseudomonas syringae pv. actinidiae (Psa), which is a major biotic stress that adversely impacts its cultivation and production. KBC control is still challenging owing to the evolution of resistant populations of Psa, the environmental risks associated with copper bactericides, and lack of effective bactericides. Therefore, to develop novel and efficient bactericides against Psa, a matrine (MT)-5-methylsalicylic acid (5-OMESA) salt (MOS) is synthesized and its antibacterial activity is analyzed. The newly synthesized compound is more antibacterial against Psa than the commercial bactericide thiazole copper (TC). MOS significantly disrupts the membrane structure of Psa and penetrates the cells more efficiently. In addition, it has high affinities to the Psa FtsZ protein and DNA helicase, which probably contribute to its bactericidal activity. Subsequently, the encapsulation of MOS into a supramolecular nanocarrier hydroxypropyl-β-cyclodextrin (HPCD) and the fabrication of a nano formulation (MOS@HPCD) result in superior solubility, penetration, foliar deposition and wettability, sustained release, and prolonged protection against Psa. The in vitro and in vivo control efficiencies of MOS@HPCD against Psa are markedly enhanced compared to those of MOS. This study proposes a promising supramolecular material to control KBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.